CD1-restricted T cell response in atherosclerosis
动脉粥样硬化中 CD1 限制性 T 细胞反应
基本信息
- 批准号:6528180
- 负责人:
- 金额:$ 32.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:CD1 molecule T lymphocyte antigen presentation antigen receptors atherosclerosis autoantigens cellular pathology clinical research cytokine gene mutation genetic polymorphism genetically modified animals human subject laboratory mouse lipids natural killer cells protein biosynthesis systemic lupus erythematosus
项目摘要
DESCRIPTION (provided by applicant):
The cluster of differentiation I (CD1) proteins represent a new class of
antigen-presenting molecules, which structurally resemble MHC class I
antigens and may restrict certain T lymphocyte responses to lipid
antigens. There are two groups of CD1 molecules encoded by five CD1
genes (CD1a, b, c, d and e). Atherosclerotic lesions contain numerous T
cells and CD1-positive macrophages and dendritic cells in addition to
chemically modified lipids (e.g., cholesterol oxides or oxysterols and
oxidized phospholipids) present in oxidized lipoproteins, raising the
possibility that CD1-restricted T cells may exist in the lesions and
respond to atherogenic lipid antigens presented by local macrophages and
dendritic cells. The specific aims of this proposal are to determine
(1) the CD1 isotype expression and CD1-restricted T cell response to
lipid components of oxidized lipoproteins in atherosclerosis; (2) the
association of an CD1 mutation or polymorphism with altered vascular
autoimmunity in patients with SLE and atherosclerosis; (3) the cytokine
production and pro-apoptotic function of CD1d-restricted NK T cells that
are reactive to lipid antigens; and (4) the impact of knocking out CD1d
gene on the T cell responses to lipid antigens and the development of
atherosclerosis caused by apolipoprotein-E deficiency. The experimental
procedures involve the analysis of T cell cytokine production and
antigen receptor profiles, the evaluation of T cell response to CD1-
lipid complexes, the assessment of genomic DNA sequences for CD1 genes,
and the histopathological characterization of atherosclerotic lesions in
the CD1/apolipoprotein-E double knockout mice recently established in
our lab. Accomplishment of this project is anticipated to generate
valuable information that help understand the immune mechanisms
underlying vascular injury during atherogenesis.
描述(由申请人提供):
分化簇I(CD 1)蛋白代表了一类新的分化簇。
抗原呈递分子,其结构类似于MHC I类
抗原,并可能限制某些T淋巴细胞对脂质的反应
抗原有两组CD 1分子由5个CD 1
基因(CD 1a、B、c、d和e)。动脉粥样硬化病变含有大量T
细胞和CD 1阳性巨噬细胞和树突状细胞,
化学修饰的脂质(例如,胆固醇氧化物或氧固醇,
氧化磷脂)存在于氧化脂蛋白中,
CD 1-限制性T细胞可能存在于病变中,
对局部巨噬细胞呈递的致动脉粥样硬化脂质抗原有反应,
树突状细胞本提案的具体目的是确定
(1)CD 1同种型表达和CD 1限制性T细胞对
动脉粥样硬化中氧化脂蛋白的脂质成分;(2)
CD 1突变或多态性与血管病变的相关性
SLE和动脉粥样硬化患者的自身免疫;(3)细胞因子
CD 1d限制性NK T细胞的产生和促凋亡功能,
对脂质抗原有反应性;和(4)敲除CD 1d的影响
基因对T细胞对脂质抗原反应的影响,
由载脂蛋白E缺乏引起的动脉粥样硬化。实验
程序涉及T细胞细胞因子产生的分析,
抗原受体谱,评估T细胞对CD 1-
脂质复合物,CD 1基因的基因组DNA序列评估,
和动脉粥样硬化病变的组织病理学特征,
最近建立的CD 1/载脂蛋白E双敲除小鼠,
我们的实验室预计该项目的完成将产生
有价值的信息,有助于了解免疫机制,
动脉粥样硬化形成过程中潜在的血管损伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yong-Jian Geng其他文献
Yong-Jian Geng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yong-Jian Geng', 18)}}的其他基金
CD1-restricted T cell response in atherosclerosis
动脉粥样硬化中 CD1 限制性 T 细胞反应
- 批准号:
6781860 - 财政年份:2001
- 资助金额:
$ 32.31万 - 项目类别:
CD1-RESTRICTED T CELL RESPONSE IN ATHEROSCLEROSIS
动脉粥样硬化中 CD1 限制的 T 细胞反应
- 批准号:
6744661 - 财政年份:2001
- 资助金额:
$ 32.31万 - 项目类别:
CD1-restricted T cell response in atherosclerosis
动脉粥样硬化中 CD1 限制性 T 细胞反应
- 批准号:
6618061 - 财政年份:2001
- 资助金额:
$ 32.31万 - 项目类别:
CD1-restricted T cell response in atherosclerosis
动脉粥样硬化中 CD1 限制性 T 细胞反应
- 批准号:
6661075 - 财政年份:2001
- 资助金额:
$ 32.31万 - 项目类别:
CD1-restricted T cell response in atherosclerosis
动脉粥样硬化中 CD1 限制性 T 细胞反应
- 批准号:
6442758 - 财政年份:2001
- 资助金额:
$ 32.31万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 32.31万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 32.31万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 32.31万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 32.31万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




